Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276

Watchlist Manager
Jiangsu Hengrui Pharmaceuticals Co Ltd Logo
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Watchlist
Price: 45.85 CNY -0.86%
Market Cap: 292.5B CNY
Have any thoughts about
Jiangsu Hengrui Pharmaceuticals Co Ltd?
Write Note

Jiangsu Hengrui Pharmaceuticals Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jiangsu Hengrui Pharmaceuticals Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accounts Payable
ÂĄ1.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
15%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accounts Payable
ÂĄ163.8m
CAGR 3-Years
10%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accounts Payable
ÂĄ470.9m
CAGR 3-Years
23%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accounts Payable
ÂĄ4.5B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
7%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Accounts Payable
ÂĄ247.3m
CAGR 3-Years
55%
CAGR 5-Years
29%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accounts Payable
ÂĄ307.9m
CAGR 3-Years
65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View

Market Cap
292.5B CNY
Industry
Pharmaceuticals

Nestled in the throbbing economic heart of China's Jiangsu province, Jiangsu Hengrui Pharmaceuticals Co Ltd has carved a niche as a formidable player in the global pharmaceutical landscape. Established in 1970, this company has evolved from its humble beginnings into a powerhouse known for its relentless focus on research and development, a keystone in its operational strategy. Hengrui has built a diverse portfolio of products, primarily focusing on oncological, cardiovascular, and anti-diabetic therapeutics. The company leverages its state-of-the-art R&D facilities and a team of top-tier scientists to innovate and advance new treatment solutions, which are then patented to ensure exclusivity and competitive market positioning. In addition to its robust R&D-driven pipeline, Hengrui thrives through strategic collaborations and international partnerships that enhance its market reach and deepen its competitive moat. Revenue generation springs from a dual-engine model: sales of proprietary drugs and a burgeoning generic drug segment that ensures steady cash flow. Furthermore, Hengrui's ability to navigate the intricate regulatory landscapes of different countries enables it to market its innovative therapies globally, thus broadening its revenue streams. With an eye toward sustainable growth, the company continually reinvests a significant portion of its profits back into R&D, sustaining its cycle of innovation and market leadership, while also playing a vital role in meeting global healthcare needs.

Intrinsic Value
34.81 CNY
Overvaluation 24%
Intrinsic Value
Price

See Also

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Accounts Payable?
Accounts Payable
1.4B CNY

Based on the financial report for Sep 30, 2024, Jiangsu Hengrui Pharmaceuticals Co Ltd's Accounts Payable amounts to 1.4B CNY.

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
15%

Over the last year, the Accounts Payable growth was 0%.

Back to Top